Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia and/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines and/or vision loss, sensory symptoms
of pins and needles and/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms and/or unilateral sensory symptoms or at least 1 aura symptom develops gradually over ≥5 minutes and/or different aura symptoms that occur in succession over ≥5 minutes.
Not only does fremanezumab lead to sustained reduction in migraine days, it also lessens the need for migraine-related acute medications and medical consultations, suggest studies presented at the American Headache Society (AHS) 2021 Scientific Session.
The novel CGRP receptor antagonist zavegepant administered intranasally effectively reduces pain and the most bothersome symptom (MBS) in patients with migraine, shows a study presented at the AAN 2021 Annual Meeting.
Intravenous eptinezumab has demonstrated early and sustained migraine-preventive effects with a favourable safety profile in adult patients with episodic migraine, according to the 1-year results of the phase III PROMISE-1* study.
Remote electrical neurostimulation delivered via a device worn around the upper arm provides consistent relief in acute migraine patients treated in a real-world clinical setting, reducing the use of medications while having a favourable safety profile, as shown in a study.
The centrally penetrant, selective serotonin 1F (5‐HT1F) receptor agonist lasmiditan appears to adversely affect driving performance at 1.5 hours postdose, but this effect disappears after 8 hours, as shown in a crossover trial.
In patients diagnosed with chronic migraine and medication-overuse headache (MOH), treatment with eptinezumab led to improved patient-reported outcomes, fewer migraine days, and a reduction in acute medication use, according to subgroup analyses of the PROMISE-2* trial presented at AHS 2020.
A single oral dose of rimegepant offers rapid, sustained pain relief for the acute treatment of migraine, thus allowing early return to normal function without the need for repeat dosing or rescue medications, results of three phase III studies presented at the AHS 2020 Meeting have shown.